SunTrust Banks, Inc. reaffirmed their buy rating on shares of Stryker Corporation (NYSE:SYK) in a research note released on Monday morning. The firm currently has a $161.00 price target on the medical technology company’s stock.

A number of other research firms also recently commented on SYK. Cowen and Company restated a buy rating and issued a $160.00 price objective (up from $150.00) on shares of Stryker Corporation in a report on Sunday, July 30th. Zacks Investment Research downgraded Stryker Corporation from a buy rating to a hold rating in a report on Thursday, August 17th. BidaskClub upgraded Stryker Corporation from a hold rating to a buy rating in a report on Thursday, August 17th. Royal Bank Of Canada raised their price objective on Stryker Corporation from $140.00 to $155.00 and gave the stock an outperform rating in a report on Friday, July 28th. Finally, Oppenheimer Holdings, Inc. set a $148.00 price objective on Stryker Corporation and gave the stock a hold rating in a report on Friday, July 28th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have assigned a buy rating to the company. The stock has an average rating of Hold and an average target price of $146.78.

Shares of Stryker Corporation (NYSE SYK) opened at 145.97 on Monday. The stock has a market capitalization of $54.60 billion, a price-to-earnings ratio of 32.58 and a beta of 0.80. The firm’s 50-day moving average is $142.31 and its 200-day moving average is $139.81. Stryker Corporation has a 52 week low of $106.48 and a 52 week high of $148.84.

Stryker Corporation (NYSE:SYK) last released its quarterly earnings data on Thursday, July 27th. The medical technology company reported $1.53 EPS for the quarter, topping analysts’ consensus estimates of $1.51 by $0.02. The company had revenue of $3.01 billion for the quarter, compared to the consensus estimate of $2.98 billion. Stryker Corporation had a return on equity of 24.26% and a net margin of 14.22%. The company’s quarterly revenue was up 6.1% compared to the same quarter last year. During the same period last year, the business posted $1.39 EPS. On average, equities research analysts anticipate that Stryker Corporation will post $6.46 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Stryker Corporation’s (SYK) “Buy” Rating Reiterated at SunTrust Banks, Inc.” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/10/05/stryker-corporations-syk-buy-rating-reiterated-at-suntrust-banks-inc.html.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 31st. Shareholders of record on Friday, September 29th will be paid a dividend of $0.425 per share. The ex-dividend date is Thursday, September 28th. This represents a $1.70 dividend on an annualized basis and a yield of 1.16%. Stryker Corporation’s dividend payout ratio (DPR) is presently 37.95%.

In other news, insider Graham A. Mclean sold 1,124 shares of Stryker Corporation stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $146.26, for a total value of $164,396.24. Following the completion of the transaction, the insider now owns 8,983 shares in the company, valued at approximately $1,313,853.58. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Lonny J. Carpenter sold 5,000 shares of Stryker Corporation stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $146.36, for a total value of $731,800.00. Following the completion of the transaction, the insider now owns 88,207 shares of the company’s stock, valued at approximately $12,909,976.52. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 25,429 shares of company stock valued at $3,686,927. 7.40% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently modified their holdings of SYK. BlackRock Inc. grew its position in shares of Stryker Corporation by 2,526.4% in the 1st quarter. BlackRock Inc. now owns 21,976,771 shares of the medical technology company’s stock worth $2,893,242,000 after acquiring an additional 21,140,000 shares in the last quarter. Koch Industries Inc. grew its position in shares of Stryker Corporation by 34,120.3% in the 2nd quarter. Koch Industries Inc. now owns 1,260,675 shares of the medical technology company’s stock worth $1,252,000 after acquiring an additional 1,256,991 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Stryker Corporation by 5.2% in the 1st quarter. Vanguard Group Inc. now owns 23,421,053 shares of the medical technology company’s stock worth $3,083,382,000 after acquiring an additional 1,161,688 shares in the last quarter. Janus Henderson Group PLC grew its position in shares of Stryker Corporation by 2,237.8% in the 2nd quarter. Janus Henderson Group PLC now owns 1,019,254 shares of the medical technology company’s stock worth $141,452,000 after acquiring an additional 975,656 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its position in shares of Stryker Corporation by 41.9% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,403,420 shares of the medical technology company’s stock worth $184,759,000 after acquiring an additional 414,715 shares in the last quarter. Institutional investors own 74.13% of the company’s stock.

About Stryker Corporation

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Analyst Recommendations for Stryker Corporation (NYSE:SYK)

Receive News & Stock Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related stocks with our FREE daily email newsletter.